BACKGROUND: Management options for symptomatic and infected walled-off pancreatic necrosis (WOPN) have evolved over the past decade from open surgical necrosectomy to more minimally invasive approaches. We reported the use of a combined percutaneous and endoscopic approach (dual modality drainage [DMD]) for the treatment of symptomatic and infected WOPN, with good short-term outcomes in a small cohort of patients. OBJECTIVE: To describe the long-term outcomes of 117 patients with symptomatic and infected WOPN treated by DMD. DESIGN: Review of a prospective, internal review board-approved database. SETTING: Single, North American, tertiary-care center. PATIENTS: All patients with symptomatic and infected WOPN treated by DMD at our institution between 2007 and 2012. INTERVENTION: DMD of symptomatic and infected WOPN. MAIN OUTCOME MEASUREMENTS: Disease-related mortality, pancreaticocutaneous fistula formation, need for early and late surgical intervention, procedure-related adverse events. RESULTS: A total of 117 patients underwent DMD for symptomatic and infected WOPN. A total of 103 have completed treatment, with all percutaneous drains removed. Ten patients are still undergoing treatment, and 4 patients died with percutaneous drains in place (3.4% disease-related mortality). For the patients completing therapy, the median duration of follow-up was 749.5 days. No patients required surgical necrosectomy or surgical treatment of DMD-related adverse events; 3 patients required late surgery for pain (n = 2) and gastric outlet obstruction (n = 1). There were no procedure-related deaths. In patients who have completed treatment, percutaneous drains have been removed in 100%; no patients have developed pancreaticocutaneous fistulas. LIMITATIONS: Single-center design, lack of a comparison group. CONCLUSION: DMD for symptomatic and infected WOPN results in favorable clinical outcomes; complete avoidance of pancreaticocutaneous fistulae, surgical necrosectomy, and major procedure-related adverse events, while maintaining single-digit disease-related mortality.
BACKGROUND: Management options for symptomatic and infected walled-off pancreatic necrosis (WOPN) have evolved over the past decade from open surgical necrosectomy to more minimally invasive approaches. We reported the use of a combined percutaneous and endoscopic approach (dual modality drainage [DMD]) for the treatment of symptomatic and infected WOPN, with good short-term outcomes in a small cohort of patients. OBJECTIVE: To describe the long-term outcomes of 117 patients with symptomatic and infected WOPN treated by DMD. DESIGN: Review of a prospective, internal review board-approved database. SETTING: Single, North American, tertiary-care center. PATIENTS: All patients with symptomatic and infected WOPN treated by DMD at our institution between 2007 and 2012. INTERVENTION: DMD of symptomatic and infected WOPN. MAIN OUTCOME MEASUREMENTS: Disease-related mortality, pancreaticocutaneous fistula formation, need for early and late surgical intervention, procedure-related adverse events. RESULTS: A total of 117 patients underwent DMD for symptomatic and infected WOPN. A total of 103 have completed treatment, with all percutaneous drains removed. Ten patients are still undergoing treatment, and 4 patients died with percutaneous drains in place (3.4% disease-related mortality). For the patients completing therapy, the median duration of follow-up was 749.5 days. No patients required surgical necrosectomy or surgical treatment of DMD-related adverse events; 3 patients required late surgery for pain (n = 2) and gastric outlet obstruction (n = 1). There were no procedure-related deaths. In patients who have completed treatment, percutaneous drains have been removed in 100%; no patients have developed pancreaticocutaneous fistulas. LIMITATIONS: Single-center design, lack of a comparison group. CONCLUSION:DMD for symptomatic and infected WOPN results in favorable clinical outcomes; complete avoidance of pancreaticocutaneous fistulae, surgical necrosectomy, and major procedure-related adverse events, while maintaining single-digit disease-related mortality.
Authors: Guru Trikudanathan; Hiba Hashmi; Ahmed Dirweesh; Stuart Amateau; Nabeel Azeem; Shawn Mallery; Martin L Freeman Journal: Endosc Int Open Date: 2020-04-17
Authors: Lu Ke; Wenjian Mao; Jing Zhou; Bo Ye; Gang Li; Jingzhu Zhang; Peng Wang; Zhihui Tong; John Windsor; Weiqin Li Journal: World J Surg Date: 2019-04 Impact factor: 3.352
Authors: Elham Afghani; Stephen J Pandol; Tooru Shimosegawa; Robert Sutton; Bechien U Wu; Santhi Swaroop Vege; Fred Gorelick; Morihisa Hirota; John Windsor; Simon K Lo; Martin L Freeman; Markus M Lerch; Yoshihisa Tsuji; Gil Y Melmed; Wahid Wassef; Julia Mayerle Journal: Pancreas Date: 2015-11 Impact factor: 3.327
Authors: Nadav Sahar; Richard A Kozarek; Zaheer S Kanji; Shingo Chihara; S Ian Gan; Shayan Irani; Michael Larsen; Andrew S Ross; Michael Gluck Journal: Eur J Clin Microbiol Infect Dis Date: 2018-04-19 Impact factor: 3.267
Authors: Janneke van Grinsven; Hjalmar C van Santvoort; Marja A Boermeester; Cornelis H Dejong; Casper H van Eijck; Paul Fockens; Marc G Besselink Journal: Nat Rev Gastroenterol Hepatol Date: 2016-03-09 Impact factor: 46.802